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Two groups have identified SAMHD1, a protein encoded by an Aicardi-Goutie`res Syndrome
susceptibility gene, as the factor that restricts infection of macrophages and dendritic cells with
HIV-1. Here we discuss implications of this discovery for induction of antiviral protective immunity.Introduction
In vertebrates, the innate immune system provides rapid
responses to awide diversity ofmicroorganismsand orchestrates
adaptive immune responses that are specific for individual patho-
gens. A variety of membrane-associated and cytoplasmic sen-
sors, referred to as pattern recognition receptors (PRRs), bind to
microbial products (pathogen-associated molecular patterns,
PAMPs) to initiate a diverse set of signaling pathways that restrict
growth of the offending organism. Antiviral responses are typically
marked by induction of type I interferon (IFN) through sensors that
recognize viral nucleic acids. These responses inhibit viral replica-
tion by myriad mechanisms and also enhance the ability of
antigen-presenting cells to prime the adaptive immune system,
promoting viral clearance and immunological memory. In turn,
viruses have evolved multiple means of circumventing innate
defense mechanisms, ensuring their survival and transmission.
HIV-1 and other retroviruses are unusual as they do not appear
to directly alert host innate defenses to their presence, and HIV-1
does not seem to induce IFN in its major target cells, the CD4+ T
lymphocytes. However, HIV-infected individuals often suffer not
only from immunodeficiency characterized by progressive loss
of CD4+ T cells but also from generalized immune activation,
with elevated cytokine and immunoglobulin levels. The high level
of circulating type I IFN in AIDS patients is therefore often consid-
ered to be due to an innate antiviral response, but the absence of
IFN secretion by infected cells suggests that it is an indirect
consequence of infection. Early after infection, extensive viral
replication and T cell loss are most apparent in the intestinal
lamina propria, where cells of the immune system regulate the
balance of the commensal microbiota and the integrity of the
mucosal epithelial barrier. AIDS-associated immune activation
has been proposed to be a consequence of a breakdown of
the mucosal barrier and the leakage of bacterial products into
the circulation (Brenchley et al., 2006). The elevated levels of
type I IFN may thus reflect failure of barrier function, opportu-
nistic infections, or changes in the composition of the intestinal
microbiota. Uptake of debris from HIV-infected T cells by plas-
macytoid dendritic cells (pDCs) may also activate innate
signaling and production of type I IFN by these specialized cells(Lepelley et al., 2011). Due to timing and proximity, these indirect
mechanisms for induction of type I IFN may not be effective in
limiting replication of HIV-1, which is highly sensitive to IFN,
andmay not contribute effectively to enhancing antiviral adaptive
immunity. The failure of the virus to be directly recognized by the
innate immune system may thus underlie, at least in part, the
difficulty in generating sterilizing immune responses in infected
individuals and the failures, thus far, of HIV vaccine trials.
The absence of IFN induction upon infection with HIV-1 may
reflect a virulence strategy of the virus. It is also possible that
retroviral replication intermediates may be subject to processes
that have evolved to prevent potentially detrimental activation of
innate immune sensors by nucleic acid byproducts generated in
the course of normal cell growth. Indeed, several studies pub-
lished during the past year indicate that mammalian cells have
mechanisms for responding to HIV-1 through activation of innate
sensors, but such responses areminimized by virus-specific and
general host physiological processes (Doitsh et al., 2010; Lepel-
ley et al., 2011; Yan and Lieberman, 2011). Here we review some
of the recent advances (Hrecka et al., 2011; Laguette et al., 2011)
in our understanding of innate responses to infection with HIV-1
and related lentiviruses and discuss these in the context of host
protection and vaccine strategy.
Aicardi-Goutie`res Syndrome Genes in Restriction
of HIV-1 Replication and Innate Sensing
Type I IFN is tightly regulated to ensure rapid antimicrobial
responses while avoiding potential damage to the host. A spec-
trum of human inflammatory diseases with manifestations re-
sembling chronic viral infection, including Aicardi-Goutie`res
Syndrome (AGS)and familial chilblain lupus,havebeenassociated
with unchecked production of type I IFN. The best characterized
genetic defects in AGS patients affect the activity of TREX1, a 30
to 50 exonuclease whose absence leads to accumulation of cyto-
plasmic single-stranded DNA (ssDNA). Such misplaced excess
DNA, which may be derived from excision-mediated DNA repair
or retrotransposition (Stetson et al., 2008), is thought to activate
a thus far unidentified cytoplasmic DNA sensor(s) (Barber, 2011).
Recently, Yan et al. (2010) found that inactivation of TREX1 inCell 147, October 14, 2011 ª2011 Elsevier Inc. 271
Figure 1. Interactions of TREX1 and SAMHD1 with
Incoming HIV-1
(A) Left panel: Cells expressing TREX1 degrade a fraction of
the reverse-transcribed DNA after viral entry. Another fraction
of viral DNA that escapes this process integrates in the host
genome without alerting innate sensors. Right panel: In cells
deficient for TREX1, the viral DNA normally degraded by
TREX1 accumulates, leading to activation of a STING- and
IRF3-dependent innate sensing pathway.
(B) Left panel: SAMHD1 in macrophages or DCs blocks
reverse transcription at a step that coincides with the minus-
strand strong stop (MSSS DNA), thus interrupting the repli-
cation cycle of the virus before integration. Right panel: HIV-2
and SIVmac express the accessory protein Vpx, which is
encapsidated within viral particles. When the virus fuses with
the target cells, Vpx is physically deliveredwithin the target cell
cytosol along with the viral core. Vpx bridges a ubiquitin ligase
complex containing at least CUL4, DDB1, and DCAF1 to
SAMHD1, leading to its proteasome-dependent degradation.
In the absence of SAMHD1, reverse transcription is no longer
restricted and viral cDNA (dsDNA) is synthesized and inte-
grated.a variety of cell types infected with HIV-1 resulted in enhanced
expression of type I IFN. In the absence of TREX1, HIV infection
was sensedbyamechanism that required the signalingmolecules
STING, TBK1, and IRF3, all of which had been previously impli-
cated inactivationof IFNexpression in response to viral infections.
IFN production was blocked by a reverse-transcriptase inhibitor,
indicating a requirement for conversion of viral RNA into DNA,
but it was not affectedby integrase inhibition, indicating that inser-
tion of the provirus in the target cell genome and expression of
additional viral products were not required. Furthermore, the
absenceofTREX1potentiatedsensingofssDNAhybridmolecules
andhada lesspronouncedeffectonssRNA,RNA:DNA,ordouble-
strandedDNA (dsDNA) sensing. Thus, an ssDNA intermediate that
occurs during HIV-1 reverse transcription, after first-strand
synthesis, likely constitutes the analog substrate sensed in cells
defective for TREX1 (Figure 1A).
TREX1 mutations account for a large proportion of AGS
patients, but mutations in SAMHD1, RNASEH2A, RNASEH2B,
and RNASEH2C also result in AGS and related diseases. All of
these molecules are thought to also have enzymatic activities
that regulate nucleic acid catabolism. Two recent studies have
shown that SAMHD1additionally has an important role in restrict-
ing the replication of HIV-1 in cells of the myeloid lineage (Hrecka
et al., 2011; Laguette et al., 2011). HIV-1 and the related primate272 Cell 147, October 14, 2011 ª2011 Elsevier Inc.lentiviruses HIV-2 and SIV infect cells that express
CD4 and an appropriate chemokine receptor,
usually CCR5 and occasionally CXCR4 or other
receptors. This receptor restriction limits the host
range of viral entry to T helper cells and myeloid
cells, including macrophages and dendritic cells
(DCs). However, the magnitude of infection with
HIV-1 is cell type specific. Human peripheral
CD4+ T cells are more susceptible to infection
with HIV-1 than macrophages or DCs. DCs are
poorly infected in culture, and it remains unclear
towhat extent they are infected in patients. Despite
their relative resistance to infectionwithHIV-1,DCshave a unique capacity to take up intact viral particles and hand
them off to susceptible T cells, thus enhancing T cell infection
in trans. This phenomenon of trans-enhancement highlights the
ability of HIV-1 to potentially exploit the cellular traffickingmachi-
nery ofDCswhile avoiding activation of the innate immune recog-
nition pathways in these cells (Izquierdo-Useros et al., 2010).
The presence of a myeloid-specific factor(s) that restricts
HIV-1 infection was originally suggested by studies aimed at
characterizing the potency of retroviral vectors in mediating
gene transduction, for use in gene therapy (Mangeot et al.,
2002). Later studies demonstrated that a myeloid cell-specific
dominant restriction factor limits the extent of reverse transcrip-
tion following viral entry. The restriction also limited infection with
HIV-2 and SIVmac if these viruses were defective for the acces-
sory protein Vpx, which is not encoded by HIV-1. Remarkably,
Vpx delivery by virus-like particles (VLPs) could alleviate the
block to infection of monocyte-derived dendritic cells (MDDC)
with HIV-1 (Goujon et al., 2006). Along with a series of biochem-
ical studies that implicated Vpx in recruiting an E3 ubiquitin
ligase, this finding suggested that Vpx mediates degradation of
the myeloid restriction factor.
Laguette et al. and Hrecka et al. (Hrecka et al., 2011; Laguette
et al., 2011) have now identified SAMHD1 as the restriction factor
expressed in myeloid cells and targeted by Vpx (Figure 1B).
Laguette et al. used epitope-tagged Vpx expressed in differenti-
ated THP-1 monocytic cells to identify SAMHD1. Hrecka et al.
employed an approach based on their earlier demonstration
of a requirement for the DCAF1 substrate receptor and the
DDB1-CUL4E3 ubiquitin ligase complex tomediate Vpx function
in primary macrophages (Srivastava et al., 2008). Using epitope-
tagged CUL4 and Vpx expressed in HEK293T cells, they showed
Vpx-dependent copurification of SAMHD1. Exposure of differ-
entiated THP-1 cells or monocyte-derived macrophages to
Vpx-containing SIVmac virus-like particles led to proteasome-
dependent degradation of SAMHD1. Finally, overexpression
and RNAi approaches showed that SAMHD1 is required in differ-
entiated THP-1 cells, macrophages, and MDDC for restriction to
infection with HIV-1.
It remains unclear why SAMHD1 restricts infection of myeloid
cells but not other cells with HIV-1. Biochemical association of
Vpx with SAMHD1 was observed in nonmyeloid cell lines that
can be readily infected without the need for Vpx. Intriguingly,
the restriction does not occur in SAMHD1-expressing THP-1
cells when they are cycling but requires differentiation-induced
cell-cycle arrest. This observation suggests that the restriction
may apply to a broader category of noncycling cells, such as
resting CD4+ T lymphocytes. It is possible that, in cycling cells,
SAMHD1 is directed toward sites for degrading host nucleic
acids generated during DNA replication and thus spares the in-
coming viral genome. Although the precise function of SAMHD1
is not known, molecules with similar sequence have been shown
to have nucleoside phosphohydrolase activity (Aravind and Koo-
nin, 1998). Like TREX1, SAMHD1 may thus assist in restraining
aberrant activation of innate immune sensors by eliminating
excess or misplaced nucleic acids, and the same enzymatic
activity may also prevent synthesis of the retroviral cDNA.
Sensing of HIV-1 by Dendritic Cells
Does SAMHD1, like TREX1, limit sensing of HIV-1 nucleic acid by
the host innate immune system? A separate line of inquiry into
DC innate responses to HIV-1 suggests that this may be so.
Unexpectedly, when the restriction to HIV-1 replication in
MDDC was relieved by delivery of Vpx, there was potent activa-
tion of an innate response marked by expression of IFN-b and
upregulation of cell-surface CD80 and CD86, which provide cos-
timulatory function for activation of T cells (Manel et al., 2010).
This response required the interaction between de novo synthe-
sized viral capsid protein (embedded in the Gag precursor) and
cellular cyclophilin A (CypA), a peptidylprolyl isomerase, leading
to phosphorylation of IRF3. Multiple lines of evidence indicated
that viral components that accumulate prior to integration (e.g.,
incoming capsid protein and viral nucleic acids) were unable to
activate DCs (Manel et al., 2010; Sunseri et al., 2011). Unlike
the case of TREX1-deficient cells, this suggests that accumula-
tion of incoming viral RNA and reverse-transcribed DNA is not
sufficient to activate DCs. Because this response required the
activity of Vpx, which is absent in HIV-1, most likely through
degradation of SAMHD1, it was termed ‘‘cryptic.’’
What is the PAMP of HIV-1 sensed in the absence of
SAMHD1?Thecontributionof capsid tosensingofHIV-1satisfies
a functional definition for a PAMP, but whether capsid itself is the
physical substrate of sensing is not known. In HIV capsid, theamino acids required for innate sensing map to a known domain
of the protein that binds to CypA. The interaction with CypA
induces a conformational change in capsid, which modulates
the efficiency and kinetics of viral uncoating—an intracellular
process leading to release of viral nucleic acid in the target cell.
More recent evidence suggests that interaction of capsid with
cellular factors also modulates a later stage in the viral life cycle,
namely the integration of the viral cDNA in the target cell genome
(Ocwieja et al., 2011). Theseproperties suggest that capsid could
regulate the availability of the viral nucleic acid to cytoplasmic
sensors. They also suggest that incoming viral capsid can have
different fates, or routes, that may influence the mechanism of
infection and, hence, the mode of innate sensing.
The discovery of SAMHD1 as the target of Vpx-induced degra-
dation raises the possibility that a viral nucleic acid that is nor-
mally targeted by SAMHD1 serves the role of a PAMPupon infec-
tion of myeloid cells with HIV-1. On this basis, we can propose
three models of cyclophilin-dependent sensing of HIV, depend-
ing on the physical PAMP (Figure S1 available online). In the first
model, capsid is the physical PAMP that directly leads to innate
activation through interaction with CypA and an appropriate
sensor. BecauseDCactivationwas not observedwhen incoming
capsid alone was present in cells, a specific feature of newly
synthesized capsid, such as subcellular trafficking, leads to
sensing. In a second model, a viral nucleic acid is the physical
PAMP. To release this PAMP, CypA recruitment when capsid is
newly made would affect remaining incoming viral cores, leading
to activation of an innate sensor(s). In a third model, the PAMP is
unknown. CypA complexed to or enabled by newly synthesized
capsid acts as a chaperone for the sensor, facilitating its interac-
tionwith the unknownPAMP, which could be anymolecule, such
as nucleic acids normally targeted by TREX1 or SAMHD1. The
last two models would, potentially, permit sensing of intact
nucleic acid (e.g., reverse-transcribed ssDNA) even in the pres-
ence of TREX1. We do not know, however, whether TREX1
activity requires SAMHD1. Alternatively, a subset viral ssDNA
may be protected from TREX1-mediated degradation by the
capsid-CypA complex. Vpx-mediated degradation of SAMHD1
in DCs and macrophages would then prevent degradation of
nucleic acids that activate a sensor. Intriguingly, type I IFN in-
duction is generally not observed in T cells or other nonmyeloid
cells infected productively with HIV, regardless of whether Vpx
is present. This suggests the existence of myeloid-specific pro-
perties of the viral PAMP, TREX1, SAMHD1, or the sensor.
A major goal now is to identify one or more sensors involved in
activation of the type I IFN response in infected cells. It is likely
that a sensor for DNA has an important role not only in mediating
the response to lentivirus infection but also in promoting inflam-
mation in AGS and related lupus-like diseases.
Coupling of HIV Innate Sensing with Adaptive Immunity
The recent findings outlined above suggest that, by unleashing
the intrinsic capacity of HIV-1 to activate innate immune sensors,
it may be possible to better control and prevent infection. Early
mucosal production of type I IFN by resident sentinel cells would
effectively limit or delay replication in infected CD4+ T cells and
spread of the infection. Activation of DCs following their produc-
tive infection at mucosal sites could further enhance adaptiveCell 147, October 14, 2011 ª2011 Elsevier Inc. 273
immune responses that are, in most cases, limited and only
partially effective. DCs have a central role in linking innate and
adaptive responses. They prime expansion of naive antigen-
specific T cells but also control key aspects of the effector phase
of adaptive immunity, including polarization of CD4+ T cells, anti-
body affinity maturation and isotype switching, homing proper-
ties of lymphocytes, establishment of memory, and regulation
of cellular exhaustion. Such ‘‘shaping’’ of the adaptive immune
response can be influenced by the type of DC and also by the
type of innate stimulus and can impact the outcome of an
immune response. The elicited effector functions important for
the adaptive arm of the immune system to control HIV-1 have
not been well defined, but it is likely that both cellular and
humoral responses are required. For instance, priming of anti-
viral CD8+ T cells is generally attributed to cross-presentation
of antigen by specialized DCs that engulf material from infected
cells. Direct infection of DCs by HIV in the presence of Vpx may
result in a different spectrum of presented antigens and in qual-
itatively or quantitatively different immune responses.
The most effective protection against viruses is provided by
live attenuated vaccines that activate both innate and adaptive
immune responses (Pulendran and Ahmed, 2011). Although
there has been little comparison between wild-type viruses
and the related attenuated vaccine strains for innate responses
that they elicit, it is likely that the effectiveness of the live atten-
uated vaccines is at least in part due to activation of host
responses that have evolved to deal most effectively with that
pathogen. In line with this argument, an effective host response
against primate lentiviruses may have evolved but may not be
engaged upon infection with HIV-1 due to activity of enzymes
such as TREX1 and SAMHD1. HIV-2, a lentivirus that can over-
come the host restriction through expression of Vpx, can pro-
ductively infect and activate DCs (Manel et al., 2010). It is note-
worthy that individuals infected with HIV-2 appear to have
a better outcome than those infected with HIV-1. It will be impor-
tant to determine whether the control of infection in these
patients is due to induction of Vpx-dependent innate and adap-
tive immune responses. Insight into mechanisms of viral control
may also come from studies of cohorts of ‘‘elite controllers,’’
whose immune defenses effectively restrict viral replication
(Sa´ez-Cirio´n et al., 2011). It is possible that at least some elite
controllers have enhanced innate responses upon infection or
may be able to restrict HIV-1 replication in T cells through mech-
anisms similar to those in myeloid cells.
Implications of HIV-1 Sensing for Control of Infection
and for Vaccine Development
An immune response to HIV-1 occurs in pathogenic infection but
is not generally protective, partly because it fuels viral replication
and contributes to inflammation. As DCs express SAMHD1, a
cell-autonomous innate response to the virus is restrained. The
immune response to HIV-1 may compensate inefficiently for the
absence of this innate response, leading to immunopathology
(Nish and Medzhitov, 2011). Activation of the cryptic innate
immune pathwaymay help to control viral replication, for instance
through antiviral effects of IFN and improved priming of HIV-
specific T cells by DC, which would reduce the burden of control
and the pool of activated CD4+ T cells available for infection.274 Cell 147, October 14, 2011 ª2011 Elsevier Inc.The recent discoveries suggest that it may be possible to
harness the innate immune response to HIV-1 for therapeutic
and prophylactic vaccination. For example, strategies aimed at
inhibiting SAMHD1 activity, allowing infection and activation of
DC, could potentially enhance the quality and quantity of virus-
specific adaptive immunity. In this context, it will be important
to understand the impact of innate immune activation on host
protection in patients infected with HIV-2 and in SIV-infected
nonhuman primates. Approaches that incorporate HIV-specific
activation of innate immunity may therefore be important for
future design of HIV therapies and vaccines.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article online at doi:10.1016/j.cell.2011.09.010.
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